27525173|t|Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy
27525173|a|Exon-skipping via synthetic antisense oligonucleotides represents one of the most promising potential therapies for Duchenne muscular dystrophy (DMD), yet this approach is highly sequence-specific and thus each oligonucleotide is of benefit to only a subset of patients. The discovery that dystrophin mRNA is subject to translational suppression by the microRNA miR31, and that miR31 is elevated in the muscle of DMD patients, raises the possibility that the same oligonucleotide chemistries employed for exon skipping could be directed toward relieving this translational block. This approach would act synergistically with exon skipping where possible, but by targeting the 3'UTR it would further be of benefit to the many DMD patients who express low levels of in-frame transcript. We here present investigations into the feasibility of combining exon skipping with several different strategies for miR31 - modulation, using both in vitro models and the mdx mouse (the classical animal model of DMD), and monitoring effects on dystrophin at the transcriptional and translational level. We show that despite promising results from our cell culture model, our in vivo data failed to demonstrate similarly reproducible enhancement of dystrophin translation, suggesting that miR31 - modulation may not be practical under current oligonucleotide approaches. Possible explanations for this disappointing outcome are discussed, along with suggestions for future investigations.
27525173	14	23	Synthetic	T114	C0597550
27525173	24	39	Oligonucleotide	T114	C0028953
27525173	53	58	Mir31	T114	C2607480
27525173	62	89	Duchenne Muscular Dystrophy	T047	C0013264
27525173	90	103	Exon-skipping	T045	C0035687
27525173	108	117	synthetic	T114	C0597550
27525173	118	144	antisense oligonucleotides	T114,T123,T130	C0079925
27525173	192	201	therapies	T061	C0087111
27525173	206	233	Duchenne muscular dystrophy	T047	C0013264
27525173	235	238	DMD	T047	C0013264
27525173	269	286	sequence-specific	T045	C1624609
27525173	301	316	oligonucleotide	T114	C0028953
27525173	351	359	patients	T101	C0030705
27525173	365	374	discovery	T052	C1880355
27525173	380	390	dystrophin	T116,T123	C0079259
27525173	391	395	mRNA	T114,T123	C0035696
27525173	410	435	translational suppression	T045	C1519619
27525173	443	451	microRNA	T114,T123	C1101610
27525173	452	457	miR31	T114	C2607480
27525173	468	473	miR31	T114	C2607480
27525173	493	499	muscle	T024	C0026845
27525173	503	506	DMD	T047	C0013264
27525173	507	515	patients	T101	C0030705
27525173	554	569	oligonucleotide	T114	C0028953
27525173	595	608	exon skipping	T045	C0035687
27525173	649	668	translational block	T045	C1519619
27525173	694	709	synergistically	T080	C2986495
27525173	715	728	exon skipping	T045	C0035687
27525173	766	771	3'UTR	T086,T123	C0600600
27525173	815	818	DMD	T047	C0013264
27525173	819	827	patients	T101	C0030705
27525173	854	862	in-frame	T086	C0080089
27525173	863	873	transcript	T114	C1519595
27525173	891	905	investigations	T058	C1261322
27525173	940	953	exon skipping	T045	C0035687
27525173	992	997	miR31	T114	C2607480
27525173	1000	1010	modulation	UnknownType	C0678672
27525173	1023	1031	in vitro	T059,T062	C3850137
27525173	1032	1038	models	T075	C0026339
27525173	1047	1056	mdx mouse	T015	C0206535
27525173	1072	1084	animal model	T008	C0599779
27525173	1088	1091	DMD	T047	C0013264
27525173	1098	1108	monitoring	T058	C1283169
27525173	1109	1116	effects	T080	C1280500
27525173	1120	1130	dystrophin	T116,T123	C0079259
27525173	1138	1153	transcriptional	T045	C0040649
27525173	1158	1171	translational	T045	C1519614
27525173	1227	1239	cell culture	T059	C0007585
27525173	1240	1245	model	T075	C0026339
27525173	1251	1258	in vivo	T082	C1515655
27525173	1259	1263	data	T078	C1511726
27525173	1309	1320	enhancement	T052	C2349975
27525173	1324	1334	dystrophin	T116,T123	C0079259
27525173	1335	1346	translation	T045	C1519614
27525173	1364	1369	miR31	T114	C2607480
27525173	1372	1382	modulation	UnknownType	C0678672
27525173	1418	1433	oligonucleotide	T114	C0028953
27525173	1491	1498	outcome	T080	C0085415
27525173	1548	1562	investigations	T058	C1261322